Abstract
Influenza A and influenza B viruses are continuing causes of morbidity and mortality on an annual basis. Influenza A viruses have historically caused periodic pandemics in the human population, sometimes with devastating consequences, such as in 1918. Fears of a new pandemic have increased in recent years because of continuing outbreaks of highly pathogenic H5N1 avian influenza viruses in birds with occasional, but often lethal infection of humans. Despite their importance as human pathogens, the antiviral drugs approved to treat influenza virus infections are currently limited to two targets, the viral neuraminidase and the viral ion channel, M2. The use of the M2 inhibitors amantadine and rimantadine is further limited by the propensity of these drugs to select for drug resistant variants. However, the replication cycle of influenza viruses has been intensively studied and is receiving increased attention. New opportunities exist to develop novel antiviral strategies targeting these viruses.
Keywords: Amantadine, influenza virus, ion channel, neuraminidase, neuraminidase inhibitor, pandemic, pathogenesis, rimantadine
Infectious Disorders - Drug Targets
Title: Influenza Viruses: Basic Biology and Potential Drug Targets
Volume: 7 Issue: 4
Author(s): Christopher F. Basler
Affiliation:
Keywords: Amantadine, influenza virus, ion channel, neuraminidase, neuraminidase inhibitor, pandemic, pathogenesis, rimantadine
Abstract: Influenza A and influenza B viruses are continuing causes of morbidity and mortality on an annual basis. Influenza A viruses have historically caused periodic pandemics in the human population, sometimes with devastating consequences, such as in 1918. Fears of a new pandemic have increased in recent years because of continuing outbreaks of highly pathogenic H5N1 avian influenza viruses in birds with occasional, but often lethal infection of humans. Despite their importance as human pathogens, the antiviral drugs approved to treat influenza virus infections are currently limited to two targets, the viral neuraminidase and the viral ion channel, M2. The use of the M2 inhibitors amantadine and rimantadine is further limited by the propensity of these drugs to select for drug resistant variants. However, the replication cycle of influenza viruses has been intensively studied and is receiving increased attention. New opportunities exist to develop novel antiviral strategies targeting these viruses.
Export Options
About this article
Cite this article as:
Basler F. Christopher, Influenza Viruses: Basic Biology and Potential Drug Targets, Infectious Disorders - Drug Targets 2007; 7 (4) . https://dx.doi.org/10.2174/187152607783018745
DOI https://dx.doi.org/10.2174/187152607783018745 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Prediction Systems for Drug-induced Liver Injury Using In vitro Cell Culture
Drug Metabolism Letters What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Current Drug Delivery Activity of the TNF-α System in Patients with Brain Disorders and During Psychopharmacological Treatment
Current Pharmaceutical Analysis Modelling Anxiety in Humans for Drug Development
Current Neuropharmacology Pharmacological Manipulation of Brain Glycogenolysis as a Therapeutic Approach to Cerebral Ischemia
Mini-Reviews in Medicinal Chemistry Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry Modulation of Inflammatory Response Improves Myocardial Infarct Healing in Rats
Current Pharmaceutical Design NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway
Current Neurovascular Research The Role of Autophagy in the Gut Pathogens Clearance and Evasion
Current Protein & Peptide Science Biodefense Properties of Milk: The Role of Antimicrobial Proteins and Peptides
Current Pharmaceutical Design Preface [Hot topic: Insulin Resistance and Impaired Coronary Endothelial Function (Guest Editor: Teruo Inoue)]
Current Drug Targets - Cardiovascular & Hematological Disorders Selenium Derivatives as Cancer Preventive Agents
Current Medicinal Chemistry - Anti-Cancer Agents Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology IL-4 and IL-13: Their Pathological Roles in Allergic Diseases and their Potential in Developing New Therapies-Update
Medicinal Chemistry Reviews - Online (Discontinued) MicroRNA-212-3p Attenuates Neuropathic Pain via Targeting Sodium Voltage-gated Channel Alpha Subunit 3 (NaV 1.3)
Current Neurovascular Research Filaggrin in Atopic Dermatitis: Flaky Tail Mice as a Novel Model for Developing Drug Targets in Atopic Dermatitis
Inflammation & Allergy - Drug Targets (Discontinued) Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy ET-18-OCH3 (Edelfosine): A Selective Antitumour Lipid Targeting Apoptosis Through Intracellular Activation of Fas / CD95 Death Receptor
Current Medicinal Chemistry IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets